View More
In patients with previously treated HER2+ metastatic CRC, T-DXd associated with a response rate of 45% and durable responses.
Neoadjuvant mFOLFIRINOX prior to chemoradiotherapy and total mesorectal excision significantly improved several efficacy outcomes vs preoperative chemoradiotherapy and total mesorectal excision.
The addition of neoadjuvant/adjuvant trastuzumab to neoadjuvant chemoradiotherapy and surgery did not improve DFS, OS, or pCR vs trimodality therapy alone in patients with HER2-positive esophageal adenocarcinoma.
The S1505 trial failed to meet primary endpoint of 2-year OS rate ≥ 58% with perioperative mFOLFIRINOX or gemcitabine/nab-paclitaxel.
In patients with advanced HER2+ gastric/GEJ cancer previously treated with trastuzumab, trastuzumab deruxtecan significantly improved response and OS vs standard chemotherapy.
Improvements in both efficacy (PFS, ORR) and safety with single-agent pembrolizumab vs standard therapy.
Contact Clinical Care Options
For customer support please email: customersupport@cealliance.com
Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191
You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.